Table 5.

Univariate 5-Year Overall Survival and Cause-Specific Survival Analyses Including Clinical and Heparanase Parameters.

Parameter	5-Year Cause-Specific Survival (%)	P	5-Year Overall Survival (%)	P	Patients at Risk
T stage
T0–2	68	.1	59	.08	21
T3	46		37		29
T4	66		28		24
N stage
N0	76	.0007	47	.096	39
N1	44		31		8
N2–3	28		26		27
ECE
Without ECE	73	.0006	55	.0005	21
With ECE	30*		24*		14
Heparanase intensity
0	100	.13	44	.4	10
1	58		41		37
2	47		34		27
Heparanase extent
0	100	.11	44	.19	10
1	69		69		12
2	51		33		52
Heparanase localization
0	100	.04	44	.03	10
Nuclear and nuclear + cytoplasmic	60		69		32
Cytoplasmic	47		26		32

Statistical significance was tested using the log-rank test.

^*Survival estimated at 24 months.

ECE, extracapsular extension.